Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Related Citations for PubMed (Select 21562248)

1.

Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.

Lee T, Li YR, Chesi A, Hart MP, Ramos D, Jethava N, Hosangadi D, Epstein J, Hodges B, Bonini NM, Gitler AD.

Neurology. 2011 Jun 14;76(24):2062-5. doi: 10.1212/WNL.0b013e31821f4447. Epub 2011 May 11.

2.

ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.

Hart MP, Gitler AD.

J Neurosci. 2012 Jul 4;32(27):9133-42. doi: 10.1523/JNEUROSCI.0996-12.2012.

3.

Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.

Conforti FL, Spataro R, Sproviero W, Mazzei R, Cavalcanti F, Condino F, Simone IL, Logroscino G, Patitucci A, Magariello A, Muglia M, Rodolico C, Valentino P, Bono F, Colletti T, Monsurrò MR, Gambardella A, La Bella V.

Neurology. 2012 Dec 11;79(24):2315-20. doi: 10.1212/WNL.0b013e318278b618. Epub 2012 Nov 28.

PMID:
23197749
4.

Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.

Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, Gispert S, Bonini NM, Andersen PM, Gitler AD.

Hum Mol Genet. 2011 May 1;20(9):1697-700. doi: 10.1093/hmg/ddr045. Epub 2011 Feb 3.

5.

Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.

Figley MD, Thomas A, Gitler AD.

Neurobiol Aging. 2014 Apr;35(4):936.e1-4. doi: 10.1016/j.neurobiolaging.2013.09.024. Epub 2013 Oct 23.

PMID:
24269018
6.

Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.

Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD.

Acta Neuropathol. 2012 Aug;124(2):221-30. doi: 10.1007/s00401-012-0985-5. Epub 2012 Apr 21.

7.

The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.

Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, Gitler AD, Becker T, Weber M, Berg D, Andersen PM, Krüger R, Riess O, Ludolph AC, Auburger G.

Neurobiol Dis. 2012 Jan;45(1):356-61. doi: 10.1016/j.nbd.2011.08.021. Epub 2011 Aug 25.

PMID:
21889984
8.

Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts.

Van Langenhove T, van der Zee J, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Mattheijssens M, Peeters K, Nuytten D, Cras P, De Deyn PP, De Jonghe P, Cruts M, Van Broeckhoven C.

Neurobiol Aging. 2012 May;33(5):1004.e17-20. doi: 10.1016/j.neurobiolaging.2011.09.025. Epub 2011 Oct 27.

PMID:
22035589
9.

PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.

Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, Kalb RG, Trojanowski JQ, Lee VM, Van Deerlin VM, Gitler AD, Bonini NM.

PLoS One. 2011 Mar 29;6(3):e17951. doi: 10.1371/journal.pone.0017951.

10.

Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.

Farg MA, Soo KY, Warraich ST, Sundaramoorthy V, Blair IP, Atkin JD.

Hum Mol Genet. 2013 Feb 15;22(4):717-28. doi: 10.1093/hmg/dds479. Epub 2012 Nov 19.

11.

Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis.

Chen Y, Huang R, Yang Y, Chen K, Song W, Pan P, Li J, Shang HF.

Neurobiol Aging. 2011 Oct;32(10):1925.e1-5. doi: 10.1016/j.neurobiolaging.2011.05.015. Epub 2011 Jul 7.

PMID:
21741123
12.

Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.

Bonini NM, Gitler AD.

J Mol Neurosci. 2011 Nov;45(3):676-83. doi: 10.1007/s12031-011-9548-9. Epub 2011 Jun 10. Review.

13.

Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders.

Lattante S, Millecamps S, Stevanin G, Rivaud-Péchoux S, Moigneu C, Camuzat A, Da Barroca S, Mundwiller E, Couarch P, Salachas F, Hannequin D, Meininger V, Pasquier F, Seilhean D, Couratier P, Danel-Brunaud V, Bonnet AM, Tranchant C, LeGuern E, Brice A, Le Ber I, Kabashi E; French Research Network on FTD and FTD-ALS.

Neurology. 2014 Sep 9;83(11):990-5. doi: 10.1212/WNL.0000000000000778. Epub 2014 Aug 6.

PMID:
25098532
14.

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rüb U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD.

Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320.

15.

ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion.

Sorarù G, Clementi M, Forzan M, Orsetti V, D'Ascenzo C, Querin G, Palmieri A, Ermani M, Angelini C, Pegoraro E.

Neurology. 2011 Jun 7;76(23):2030-1. doi: 10.1212/WNL.0b013e31821e557a. No abstract available.

PMID:
21646631
16.

Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients.

Ramos EM, Keagle P, Gillis T, Lowe P, Mysore JS, Leclerc AL, Ratti A, Ticozzi N, Gellera C, Gusella JF, Silani V, Alonso I, Brown RH Jr, MacDonald ME, Landers JE.

Amyotroph Lateral Scler. 2012 May;13(3):265-9. doi: 10.3109/17482968.2011.653573. Epub 2012 Mar 13.

PMID:
22409360
17.

Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?

van den Heuvel DM, Harschnitz O, van den Berg LH, Pasterkamp RJ.

Trends Mol Med. 2014 Jan;20(1):25-35. doi: 10.1016/j.molmed.2013.09.001. Epub 2013 Oct 16. Review.

PMID:
24140266
18.

ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population.

Lahut S, Ömür Ö, Uyan Ö, Ağım ZS, Özoğuz A, Parman Y, Deymeer F, Oflazer P, Koç F, Özçelik H, Auburger G, Başak AN.

PLoS One. 2012;7(8):e42956. doi: 10.1371/journal.pone.0042956. Epub 2012 Aug 20.

19.

De novo mutations in ataxin-2 gene and ALS risk.

Laffita-Mesa JM, Rodríguez Pupo JM, Moreno Sera R, Vázquez Mojena Y, Kourí V, Laguna-Salvia L, Martínez-Godales M, Valdevila Figueira JA, Bauer PO, Rodríguez-Labrada R, González Zaldívar Y, Paucar M, Svenningsson P, Velázquez Pérez L.

PLoS One. 2013 Aug 6;8(8):e70560. doi: 10.1371/journal.pone.0070560. Print 2013.

20.

Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis.

Neuenschwander AG, Thai KK, Figueroa KP, Pulst SM.

JAMA Neurol. 2014 Dec;71(12):1529-34. doi: 10.1001/jamaneurol.2014.2082. Erratum in: JAMA Neurol. 2015 Jan;72(1):128.

PMID:
25285812
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk